A BRIEF REVIEW ON THE THERAPEUTIC RESISTANCE AGAINST CANCER BY CANCER STEM CELL (CSC)
SUJIT KUMAR BHOWAL *
Department of Zoology, Maulana Azad College, Kolkata- 700013, India.
*Author to whom correspondence should be addressed.
Abstract
Cancer stem cells (CSCs) are small subpopulation of cells within tumours which possess characteristics associated with normal stem cell such as self-renewal and differentiation. CSCs play crucial role in cancer development by regulating the cancer cell survival, metastatic potential, disease relapse and poor prognosis. There are many cell markers like CD44, CD24, EpCAM, CD133, CXCR4, cMet, ALDH1 which can identify the CSCs.These cells are poorly regulated through cell cycle and also have metastatic ability as well as long life span. Chemotherapy is a part of successful cancer treatment. But the CSC’s multidrug resistance mechanism (MDR) like high expression of ABC transporter, histone lysine demethylase, suppression of apoptosis, progesterone receptor membrane component-1(PGRMC1) and increased expression of aldehydrogenase-1 are responsible to resist chemotherapy. Combined therapies targeting CSCs and their progenies may represent the most promising approach for the future treatment of cancer patients. This review summarizes the characterisation and identification of CSCs, different multidrug resistance mechanism of CSCs and the advanced types of treatment mechanism.
Keywords: Cancer stem cell (CSC), CSC markers, disease relapse, metastasis, multidrug resistance, selective therapy, tumours
How to Cite
Downloads
References
Li Y, Ajani J, Song S. Drug resistance and Cancer stem cells. Cell communication and signalling: CCS, 2021;19(1):19.
DOI: 10.1186/s12964-020-00627-5
Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: The origin of the cancer stem. cell: Current controversies and new insights. Nature Reviews Cancer. 2005;5:899-904.
Liu L, Yin S, Brobbey C, Gan W. Ubiquitination in cancer stem cell: Roles and targeted cancer therapy. STEMedicine. 2020; 1(3): e37.
DOI: 10.37175/stemedicine. v1i3.37
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367: 645-648.
Li Q, Wu J, Chen S, Zhao Y. Cancer stem cells: A new target for cancer therapy. Histology and Histopathology. 2018;33(12): 18004.
DOI: 10.14670/HH-18-004
Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumour Biology. 2012;32:425-440.
Huntly BJ, GillilandDG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nature Reviews Cancer. 2005;5:311-321.
Bonnet D, Dick JE. Human acute myeloid leukaemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine. 1997;7:730-737.
Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Methods in Cell Biology. 2008:311-324.
Atena M, Reza MA, Mehran G. A Review on the biology of cancer stem cell. Stem Cell Discovery. 2014;4:83-89.
Huang J, Li C, Wang Y, Lv HY, Guo YL, Dai H, et al. Cytokine-induced killer (CIK) cells bound with anti-cd3/anti-cd133 bispecific antibodies target cd133 (high) cancer stem cells in vitro and in-vivo. Clinical Immunology. 2013;149:156-168.
Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, et al. Human γδT lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. Journal of Immunology. 2012;188:1708-1716.
Braza MS, Klein B. Anti-Tumour immunotherapy with Vγ9Vδ2 T lymphocytes: From the bench to the bedside. British Journal of Haematology. 2013;160:123-132.
Resetkova E, Reis-Filho JS, JainRK, Mehta R, Thorat MA, Nakshatri H, et al. Prognostic impact of aldh1 in breast cancer: a story of stem cells and tumour microenvironment. Breast Cancer Research and Treatment. 2010;123(1):109-111.
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature Review Cancer. 2005;5:275-284.
Chuthapisith S. Cancer stem cells and chemoresistance. Cancer Stem Cells Theories and Practice, InTech, Shanghai; 2011.
DOI: 10.5772/13789
Thakur R, Mishra D. Modulation of cell death pathways in cancer stem cells: targeting histone demethylases. Advances in Bioscience and Biotechnology. 2012;3:720-730.
Stassi G, Todaro M, Zerilli M, Ricci-VitianiL, Di Liberto D, Patti M, et al. Thyroid cancer resistance to hemotherapeutic drugs via autocrine production of interleukin- 4 and interleukin-10. Cancer Research. 2003;63: 6784-6790.
Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumours. Breast Cancer Research. 2008;10:53.
Rich JN, Bao SD. Chemotherapy and cancer stem cells. Cell Stem Cell. 2007;1:353-355.
Kim SK, Kim H, Lee DH, Kim TH, Kim T, Chung C, et al. Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS ONE. 2013;8:e78130.
Available:http://dx.doi.org/10.1371/journal. pone.0078130
Wang X, Liu Q, Hou B, Zhang W, Yan M., Jia H, et al. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells. PLoS ONE. 2013;8:e73942. Available:http://dx.doi.org/10.1371/journal.pone.0073942
Shenouda S, Kulkarni K, Abuetabh Y, Sergi C. Cancer Stem Cells and their Management in Cancer Therapy. Recent Patents on Anti-Cancer Drug Discovery. 2020; 15(3).
DOI: 10.2174/1574892815666200713145931
Price JE, Tarin D. Low incidence of tumourigenicity in agarose colonies from spontaneous murine mammary tumours. Differentiation. 1989;41:202–207.
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a pre-dictor of poor clinical outcome. Cell Stem Cell. 2007;1(5): 555-567.
Ghasemi S, Xu S, Nabavi S, Amirkhani M, Sureda A, Tejada S, et al. Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting). Phytotherapy Research; 2021.
DOI: 10.1002/ptr.7059
YanW, ChenY, YaoY, Zhang H, WangT. In-creased invasion and tumourigenicity capacity of CD44+/ CD24- breast cancer mcf7 cells in-vitro and in nude mice. Cancer Cell International. 2013;13(1):62.
Dancescu M, Rubio Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic b cells from death by apoptosis and upregulates bcl-2 expression. Journal of Experimental Medicine. 1992;176:1319-1326.
Hampton KK, Stewart R, Napier D, Claudio P, Craven R. PGRMC1 levation in multiple cancers and essential role in stem cell survival. Adv Lung Cancer (Irvine). 2015;4(3): 37-51.
Signore M, Ricci-Vitiani L, De Maria R. Targeting apoptosis pathways in cancer stem cells. Cancer Letters. 2013;332: 374-382.
Avendaño C, Menéndez JC. Inhibitors of multidrug resistance to antitumour agents (MDR). Current Medicinal Chemistry. 2002;9: 159-193.
Banerjee S, Nomura A, Sangwan V, Chugh R, Dudeja V, Vickers SM, et al. CD133+ tumour initiating cells in a syngenic murine model of pancreatic cancer respond to minnelide. Clinical Cancer Research. 2014;20: 2388-2399.
Li SH, Fu J, Watkins DN, Srivastava RK, Shankar S. Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic Hedgehog-GLI pathway. Molecular and Cellular Biochemistry. 2013;373:217-227.
Herrera VL, Decano JL, Tan GA, Moran AM, Pasion KA, Matsubara Y, et al. DE spRroles in Tumour vasculo-angiogenesis, invasiveness, CSC-Survival and anoikis resistance: A common receptor coordinator paradigm. PLoS ONE. 2014;9(1):e85821.
Available:http://dx.doi.org/10.1371/journal.pone.0085821
Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, et al. Novel bispecific antibodies increase γδT-cell cytotoxicity against pancreatic cancer cells. Cancer Research. 2014; 74:1349- 1360.
Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, et al. Nodal/activin signalling drives self-renewal and tumourigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011; 9:433-446.
Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, et al. Targeting ALDHbright human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. Clinical Cancer Research, 2011;17:6174-6184.
Miyoshi N, Mizusima T, Doki Y, Mori K. Biomarkers of Cancer Stem Cells in Cancer Therapy. 2019;51-59.
DOI: 10.1007/978-981-13-7295-7_5
Garcia-MayeaY, Mir C, Masson F, Paciucci R, Leonart M. Insights into new mechanisms and models of cancer stem cell multidrug resistance. Seminars in Cancer Biology. 2020;60:166-180.
García-Heredia J, Carnero A. Role of mitochondria in cancer stem cell resistance. Cell. 2020;9(7):1693.